Match Document Document Title
US20120204276 METHODS RELATED TO A MUTATION IN COMPLEMENT FACTOR H-RELATED PROTEIN 5 IN PATIENTS WITH GLOMERULONEPHRITIS  
The invention relates to methods of regulating complement. In particular, the inventors have identified a relationship between a particular gene, CFHR5, and irregularities in complement...
US20140047569 Methods of Treating Disorders Associated with Protein Aggregation  
The present invention relates to methods of treatment of clinical disorders associated with protein aggregation comprising administering, to a subject, an effective amount of an anti-protein...
US20130024953 Methods of Treating Disorders Associated with Protein Aggregation  
The present invention relates to methods of treatment of clinical disorders associated with protein aggregation comprising administering, to a subject, an effective amount of an anti-protein...
US20140237630 SCREENING METHOD  
The present invention provides a method of screening a mammal for the onset or predisposition to the onset of a neuropsychiatric disorder. More particularly, the present invention provides a...
US20130024955 METHOD FOR DETERMINING GENOTOXICITY USING NON-FLUORESCENT PROTEINS  
The present invention relates to a method for determining a genotoxicity of a test substance, comprising the steps of: (a) transforming a fish with a nucleotide sequence encoding a non-fluorescent...
US20110055937 Keratin 8 Mutations are Risk Factors for Developing Liver Disease of Multiple Etiologies  
Keratin 8 and 18 (K8/K18) mutations are shown to be associated with a predisposition to liver or biliary tract disease, particularly noncryptogenic hepatobiliary disease. Unique K8/K18 mutations...
US20130317569 Optogenetic Control of Reward-Related Behaviors  
Provided herein are compositions and methods for disrupting at least one reward-related behavior in an individual through the use of light-responsive opsin proteins used to control the...
US20130150465 PIG MODEL FOR BREAST CANCER, MITOCHONDRIA RELATED PROTEIN FOLDING DISORDERS AND/OR EPIDERMOLYSIS BULLOSA SIMPLEX  
The present invention relates to a genetically modified pig as a model for studying breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex. The modified...
US20140150124 In Vivo Reporter System  
A construct system for expressing a reporter protein, as well as a transgenic animal and a screening method employing the same, are provided. In certain embodiments, the construct system is a...
US20110107440 SKIN CANCER ASSOCIATED MICRORNAS  
This invention relates to the finding that skin cancers, such as squamous cell carcinoma and basal cell carcinoma, are characterized by changes in the expression of specific microRNA molecules...
US20120222139 Cancer Specific Mitotic Network  
Developed here is a mitotic network comprising a signature of up to 54 genes, and including also sub-sets of genes within the signature, which can identify members by requiring higher correlation...
US20120304318 CANCER DIAGNOSIS AND TREATMENT  
The invention concerns materials and methods relating to the use of OMD (osteomodulin) and\or PRELP (Proline/arginine-rich end leucine-rich repeat protein) expression, particularly...
US20120180145 Tool for Studying Endothelial Haematopoietic Transition (EHT) and Epithelial-Mesenchymal Transition (EMT) Associated Events  
The present invention relates to the field of endothelial haematopoietic transition (EHT) and epithelial-mesenchymal transition (EMT) and more particularly relates to the use of fish embryo or...
US20110047631 HEAT SHOCK PROTEIN DEFICIENCIES AS MODEL SYSTEMS FOR BRAIN PATHOLOGY AND CANCER  
The invention provides non-human transgenic animals as models of neurodegenerative brain pathology, including, but not limited to, Alzheimer's disease (AD), and cancer. The non-human transgenic...
US20110083200 Method For Testing Efficacy Of Treatment Of Neurologic Disorders  
The method of the invention is useful for evaluating pharmaceutical compositions for treatment of neurological diseases encompassing neurological or neurodegenerative diseases associated with...
US20140187611 MITOCHONDRIAL RIBOSOMAL PROTEINS AS AGING REGULATORS  
The present invention relates to methods of increasing lifespan, delaying aging, and/or preventing or treating an age-related disease or a mitochondrial disease in a subject, comprising inducing a...
US20110041190 NOVEL CHIMERIC PROTEINS  
Novel chimeric proteins are disclosed. The proteins comprise at least two portions. The first portion binds to a first cell and decreases the cell's ability to send a trans signal to a second...
US20130347135 ANIMAL MODEL FOR PARKINSON'S DISEASE  
An animal model for Parkinson's disease has a disrupted Mfn2 gene in dopaminergic neurons.
US20100299765 MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA  
This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment...
US20110055936 TRANSGENIC MAMALS MODIFIELD IN BRI PROTEIN EXPRESSION  
Provided are non-human mammals comprising a transgenic nucleic acid sequence capable of causing an alteration of expression of Bri2 or Bri3 in the mammal. Also provided are non-human mammals...
US20110030070 DIAGNOSIS AND TREATMENT OF AUTISM USING CD38  
The invention relates to a method for screening a pharmaceutical for treating or preventing a neurodevelopmental disorder or a psychiatric disorder accompanied by an abnormality of oxytocin system...
US20110263691 METHODS CONCERNING PPAR DELTA AND ANTAGONISTS THEREOF  
Non-human animals which overexpress PPARd or which express transgenic PPARd are useful as models for inflammatory skin conditions such as psoriasis. Test substances can be screened to assess their...
US20130031644 AUTONOMOUS LUX REPORTER SYSTEM AND METHODS OF USE  
Disclosed are systems for expression of an autonomous lux reporter system in a vertebrate cell, such as mammalian or fish cell. In some examples the lux reporter system is operably connected to a...
US20120260355 Method for Evaluating Inhibitory Polynucleotide Efficiency and Efficacy  
The present invention provides a method for testing the efficiency of delivering an inhibitory polynucleotide to a target cell or tissue. The invention also provides a method for testing...
US20130111611 METHOD TO MEASURE THE METABOLIC RATE OR RATE OF GLUCOSE CONSUMPTION OF CELLS OR TISSUES WITH HIGH SPATIOTEMPORAL RESOLUTION USING A GLUCOSE NANOSENSOR  
A method to measure the metabolic rate or rate of glucose consumption of cells or tissues with high spatiotemporal resolution using a glucose nanosensor is disclosed. The method generally includes...
US20150143552 BIOCONTROL  
Provided is an arthropod male germline gene expression system suitable for conditional expression of an effector gene in an Arthropod male germline. The system comprises a first expression unit...
US20140283149 In Vivo Cellular Screening Methods and Compositions for Modeling and Treating Nervous System Dysfunction  
Described herein are methods and composition for identifying agents that modulate nerve regeneration in vivo in extended third instar (ETI) Drosophila larvae. The methods include the use of ETI...
US20110289605 Animal Model for Osteoarthritis and Intervertebral Disc Disease  
Provided herein is a transgenic animal whose genome comprises a first nucleic acid sequence encoding a fusion polypeptide, wherein the fusion polypeptide comprises a Cre recombinase and a mutated...
US20110165144 METHODS FOR TREATING RHEUMATOID ARTHRITIS  
Provided are methods of treating rheumatoid arthritis by inhibiting Neuromedin U signalling.
US20110243854 Methods and systems for identifying modulators of longevity  
Methods of treating disorders such as neurofibromatosis-1 are provided, including methods in which catalytic antioxidants such as metalloporphyrins are administered. Methods of regulating...
US20110296538 IN VIVO QUANTITATIVE SCREENING TEST FOR ANTI-METASTASIS TREATMENT EFFICACY  
The present invention is directed to methods for evaluating the efficacy of a cancer treatment for (i) inhibiting metastasis in a subject, (ii) inhibiting local cancer cell movement, and (iii)...
US20150203918 MUTATED ACVR1 FOR DIAGNOSIS AND TREATMENT OF FIBRODYPLASIA OSSIFICANS PROGRESSIVA (FOP)  
This invention is directed to mutated Activin A type I receptor proteins (ACVR1) and isolated nucleic acids encoding same. The invention also relates to the use of mutated ACVR1 in the diagnosis...
US20130139273 Chronic Lymphocytic Leukemia Modeled in Mouse by Targeted miR-29 Expression  
A mouse model and uses there of for detecting, treating, characterizing, and diagnosing various diseases are described.
US20130184321 Model Mouse of Attention Deficit Hyperactivity Disorder, Method for Investigating Effects for Preventing and Alleviating Attention Disorder using the Model Mouse, and Method for Treating Attention Disorder by Suppressing T-Type Calcium Channel  
The present invention relates to an Attention deficit and hyperactivity disorder (ADHD) mouse model and a screening method for a composition for the prevention and treatment of attention deficit...
US20110214189 G PROTEIN COUPLED RECEPTORS AND USES THEREOF  
The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are...
US20110185439 G PROTEIN COUPLED RECEPTORS AND USES THEREOF  
The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are...
US20150143553 Methods And Compositions Comprising A Drosophila Model Of Amyotrophic Lateral Sclerosis  
In an aspect, the invention relates to a method of screening for a therapeutic for amyotrophic lateral sclerosis. In an aspect, the invention relates to transgenic Drosophila. In an aspect, the...
US20150052624 GENETICALLY MODIFIED RAT MODELS FOR PAIN  
This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of gene(s) or gene product(s) resulting in altered...
US20120151609 Genetically Modified Rat Models for Pain  
This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of gene(s) or gene product(s) resulting in altered...
US20130283403 ZEBRAFISH SEIZURE MODEL, METHOD FOR ESTABLISHING THE SAME, AND METHOD FOR SCREENING ANTIEPILEPTIC DRUG USING THE SAME  
A zebrafish seizure model, a method for establishing the same, and a method for screening for antiepileptic drug using the same are disclosed. The method for establishing the zebrafish seizure...
US20140041063 Genetically Modified Rat Models for Obesity and Diabetes  
This invention relates to a genetically modified or chimeric rat cell whose genome comprises chromosomal alleles of an obesity-diabetes gene (especially, the Mc4r gene or Lep gene), wherein at...
US20140325691 REGULATION OF ENDOGENOUS GENE EXPRESSION IN CELLS USING ZINC FINGER PROTEINS  
The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.
US20110247087 Regulation of endogenous gene expression in cells using zinc finger proteins  
The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.
US20140033333 TRANSGENIC PIG FOR MUTANT GUCY2D AS CONE DYSTROPHY MODEL  
The present invention relates to a transgenic pig as a model for studying a cone affecting disease, in particular a cone dystrophy or cone-rod-dystrophy, wherein the pig model expresses a dominant...
US20100319074 MULTI-TARGETED RNAI THERAPEUTICS FOR SCARLESS WOUND HEALING OF SKIN  
The present invention provides small interfering RNA (siRNA) molecules, compositions containing them, and methods of using them for improvement of skin scarless wound healing and other skin...
US20140090095 Genetically Modified Mice and Engraftment  
A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mIl2rg subunit gene; and optionally a humanization of the TPO gene is described....
US20130331394 TREATING SCHIZOPHRENIA  
Methods of identifying new treatments for schizophrenia, and the use of the same.
US20130179997 TRANSGENIC ANIMAL EXPRESSING ALZHEIMER'S TAU PROTEIN  
The present invention provides transgenic non-human animals and non-human mammalian somatic and germ cells harbouring a human DNA sequence encoding Alzheimer's Disease (AD) derived tau protein,...
US20110296540 ASSAY FOR SCREENING ANTIDEPRESSANTS  
This invention provides a method for identifying a small molecule as an antidepressant, a method for identifying a small molecule as an anxiolytic, and a method for identifying a small molecule as...
US20110126299 TRIPLE TRANSGENIC MOUSE MODEL OF AUTOIMMUNE DISEASE AND NF-KAPPA B IN VIVO IMAGING  
The present invention provides for monitoring of NF-κB-associated inflammation in mice undergoing Id-driven autoimmune disease. The mice are triple transgenic mice expressing both Id+ B cells and...